42 related articles for article (PubMed ID: 38499069)
1. The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma.
Liu QQ; Wang XX; Ji H; Dou QY; Zhang HM
Med Oncol; 2024 Mar; 41(5):91. PubMed ID: 38526607
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion.
Zhang Y; Zhang H; Xu H; Wang Y; Feng L; Yi F
World J Surg Oncol; 2024 May; 22(1):122. PubMed ID: 38711095
[TBL] [Abstract][Full Text] [Related]
3. TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study.
Tang Z; Bai T; Wei T; Wang X; Chen J; Ye J; Li S; Wei M; Li X; Lin Y; Tang J; Li L; Wu F
BMC Cancer; 2024 Jun; 24(1):717. PubMed ID: 38862932
[TBL] [Abstract][Full Text] [Related]
4. Role of Transarterial Chemoembolization in the Era of Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Combination Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score Matched Analysis.
Zhang JX; Hua HJ; Cheng Y; Liu S; Shi HB; Zu QQ
Acad Radiol; 2024 Apr; 31(4):1304-1311. PubMed ID: 37775449
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Lenvatinib in Combination With PD-1 Monoclonal Antibody and Interventional Treatment for Intermediate-Stage Hepatocellular Carcinoma: Impact on Serum Vascular Endothelial Growth Factor and Matrix Metalloproteinase-9 Levels: A Retrospective Study.
Zhu J; Wu Y; Zhang H; Yang J; An Y; Shao S; Xia N
Technol Cancer Res Treat; 2024; 23():15330338241256812. PubMed ID: 38802996
[No Abstract] [Full Text] [Related]
6. Is the TAE score a promising prognostic predictor for unresectable hepatocellular carcinoma treated with TACE plus lenvatinib with PD‑1 inhibitors? Further validation should be performed.
Yang S; Liang H; Li X; Qian J; Ming Z
Hepatol Int; 2024 Jun; 18(3):1058-1059. PubMed ID: 38717694
[No Abstract] [Full Text] [Related]
7. Efficacy and safety of lenvatinib combined with PD‑1/PD‑L1 inhibitors in the treatment of hepatocellular carcinoma: A meta‑analysis and systematic review.
Zhang B; Su L; Lin Y
Oncol Lett; 2024 Jul; 28(1):312. PubMed ID: 38803443
[TBL] [Abstract][Full Text] [Related]
8. Transarterial chemoembolization (TACE)-hepatic arterial infusion chemotherapy (HAIC) combined with PD-1 inhibitors plus lenvatinib as a preoperative conversion therapy for nonmetastatic advanced hepatocellular carcinoma: a single center experience.
Zhao W; Liu C; Wu Y; Yao Z; Dou Q; Li W; Zhao X; Xia N
Transl Cancer Res; 2024 May; 13(5):2315-2331. PubMed ID: 38881913
[TBL] [Abstract][Full Text] [Related]
9. Lenvatinib in combination with transarterial chemoembolization vs. sorafenib in combination with transarterial chemoembolization for unresectable hepatocellular carcinoma: A network meta‑analysis.
Li Y; Liu X; Liu J; Yang L; Wei S; Li J; Gan H; Ma T; Yi P
Oncol Lett; 2024 Aug; 28(2):347. PubMed ID: 38872858
[TBL] [Abstract][Full Text] [Related]
10. Conversion surgery for initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitor: A real-world observational study.
Li X; Wang X; Bai T; Chen J; Lu S; Wei T; Tang Z; Zhao G; Lu H; Li L; Wu F
Dig Liver Dis; 2024 Jun; 56(6):1078-1086. PubMed ID: 38114383
[TBL] [Abstract][Full Text] [Related]
11. A study on combination of non-ablative local RFA with PD-1 and angiogenesis blocking to prolong survival through improvement of immune microenvironment in advanced Hepatocellular Carcinoma.
Xiao T; Hu S; Dong S; Cai Q; Gong W; Zhang Y; Long C; Li X
Int Immunopharmacol; 2024 Jun; 134():112144. PubMed ID: 38733820
[TBL] [Abstract][Full Text] [Related]
12. Role of transarterial chemoembolization for hepatocellular carcinoma with extrahepatic metastases in the era of advancing systemic therapy.
Song BG; Goh MJ; Kang W; Sinn DH; Gwak GY; Paik YH; Lee JH; Choi MS
J Liver Cancer; 2024 Jun; ():. PubMed ID: 38825874
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of circulating immune cell changes in response to PD-1 blockade and TKI therapy in patients with hepatocellular carcinoma.
Wang J; Xiao P; Li X; Wu W; Shi D; Lin W; Wu Z
Clin Res Hepatol Gastroenterol; 2024 May; 48(7):102390. PubMed ID: 38823631
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: A meta-analysis.
Wang L; Lin L; Zhou W
Pharmacol Ther; 2024 May; 257():108634. PubMed ID: 38499069
[TBL] [Abstract][Full Text] [Related]
15. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
Diao L; Wang C; You R; Leng B; Yu Z; Xu Q; Cheng Y; Yin G
J Gastroenterol Hepatol; 2024 Apr; 39(4):746-753. PubMed ID: 38240156
[TBL] [Abstract][Full Text] [Related]
16. Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study.
Cai M; Huang W; Huang J; Shi W; Guo Y; Liang L; Zhou J; Lin L; Cao B; Chen Y; Zhou J; Zhu K
Front Immunol; 2022; 13():848387. PubMed ID: 35300325
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of transarterial chemoembolization combined with lenvatinib, programmed death-1 inhibitor, and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis.
Lin LW; Yan LY; Ke K; Yang WZ; Lin JQ; Huang N
Brachytherapy; 2023; 22(6):858-871. PubMed ID: 37574351
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis.
Deng J; Liao Z; Gao J
Curr Oncol; 2023 Jan; 30(1):1243-1254. PubMed ID: 36661745
[TBL] [Abstract][Full Text] [Related]
19. Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis.
Zhang X; Wang K; Wang M; Yang G; Ye X; Wu M; Cheng S
Oncotarget; 2017 Apr; 8(17):29416-29427. PubMed ID: 28177886
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
